Country for PR: United Kingdom
Contributor: PR Newswire Europe
Thursday, October 10 2019 - 14:58
Path-breaking Study Reports High Sensitivity in Diabetic Retinopathy Screening Using Smartphones and Automated-AI in Primary-Care: Remidio Innovative
BENGALURU, India, Oct. 10, 2019 /PRNewswire-AsiaNet/ --

    Nearly 50% of patients with diabetes fail to get an annual eye examination 
done even in the US and EU. In many countries, less than 10% of patients 
referred to ophthalmologists by their primary-care physicians actually complete 
a dilated retinal examination.

    Technology can play a role in empowering primary-care physicians. 
Primary-care based Diabetic Retinopathy (DR) screening can enable early 
detection, avoiding blindness due to DR for close to 425 million people living 
with diabetes globally. 
    In a study reported in JAMA Ophthalmology, a team from Aditya Jyot 
Foundation for Twinkling Little Eyes, Mumbai, India, screened patients with 
diabetes mellitus in civic dispensaries in Mumbai with smartphone-based retinal 
cameras from Remidio Innovative Solutions and validated the diagnostic accuracy 
of the integrated Medios AI to detect DR. Medios AI provides a retinal 
diagnosis report in less than 10 seconds, with inferencing done right on the 
    The images captured on Remidio's smartphone camera were subjected to 
automated analysis by Medios AI. They were simultaneously graded by 
vitreoretinal specialists. The Medios AI is composed of two different 
algorithms based on convolutional neural networks, one assessing the 
image-quality, and the other separating healthy images from images with 
referable DR (RDR).
    The clinical sensitivity and specificity of the Medios AI algorithm were 
found to be 100% and 88.4% for RDR, 85.2% and 92.0% for any DR respectively, 
exceeding FDA's superiority end points of an RDR sensitivity of 85% and 
specificity of 82.5%.
    Dr. T.Y. Alvin Liu, MD, Assistant Professor, Ophthalmology at Johns Hopkins 
Bloomberg School of Public Health, in an invited commentary, calls the study 
    Dr. Natarajan, the lead author of the study, opines, "The study paves the 
way in implementing large-scale models for screening for DR, even in locations 
with no Internet infrastructure. This is a step ahead of the approach taken by 
Google and other AI companies that need their AI models to run on external 
servers, necessitating Internet access."
    The device and automated AI are CE marked and available for use in the EU. 
Previous clinical studies validating the same device were published in Nature 
Eye and Ophthalmology Retina.
    About Remidio Innovative Solutions:
    Remidio is the world's first integrated ophthalmic device and Artificial 
Intelligence company that uses its patented and easy-to-use products to impact 
vision screening, globally. For more information, visit:
    Media contact 
    Alok Raj K

    Source: Remidio Innovative Solutions Pvt Ltd